Cambrex Co. (NYSE:CBM) CFO Sells $9,953,840.75 in Stock

Cambrex Co. (NYSE:CBM) CFO Gregory Sargen sold 165,925 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $59.99, for a total transaction of $9,953,840.75.

CBM opened at $59.99 on Friday. The stock’s 50 day simple moving average is $59.80 and its 200 day simple moving average is $53.29. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.37 and a quick ratio of 1.70. Cambrex Co. has a 1 year low of $33.80 and a 1 year high of $60.29. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 21.66 and a beta of 2.14.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.01. The firm had revenue of $148.56 million during the quarter. Cambrex had a return on equity of 5.38% and a net margin of 5.96%.

Institutional investors have recently modified their holdings of the company. Gabelli Funds LLC bought a new stake in Cambrex during the 3rd quarter valued at $14,458,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Cambrex during the 3rd quarter valued at $9,259,000. Waddell & Reed Financial Inc. purchased a new stake in Cambrex during the 2nd quarter valued at $6,945,000. Nuveen Asset Management LLC grew its holdings in Cambrex by 349.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 180,545 shares of the biotechnology company’s stock worth $8,451,000 after acquiring an additional 140,418 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Cambrex by 2.7% in the 2nd quarter. BlackRock Inc. now owns 5,001,164 shares of the biotechnology company’s stock worth $234,103,000 after acquiring an additional 132,617 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

A number of brokerages recently commented on CBM. Zacks Investment Research cut shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. ValuEngine cut shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Finally, Craig Hallum downgraded shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a research note on Monday, August 12th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $54.83.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Further Reading: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.